Glaxosmithkine and Merck & Co succumb to the urge to demerge, joining other big drug makers in pruning their businesses.
January saw Aimmune receive an FDA approval for Palforzia, a first for peanut allergy, alongside decisions for Blueprint Medicines and Horizon Therapeutics.
It is no longer just small biotechs that are taking aim at coronavirus: Gilead Sciences and Glaxosmithkline are getting involved too, albeit via different routes.
Almost in stealth mode the Swiss firm moves to begin a huge pivotal programme rivalling that of the IDO and IL-2 mechanisms.
Digital health is a core focus for Philips. Might more acquisitions be on the way?
Pfizer’s chief executive has pledged to throw money at the pharma giant’s thin pipeline and shirk financial engineering, but only canny deal-making will keep investors on…
Investors in Conatus, and especially those in Newlink, should question how valuations of the groups' reversing acquirers have been calculated.
Sotatercept’s win in pulmonary arterial hypertension positions Acceleron for a battle against the leaders in this crowded space.
In gastric cancer the Astra/Daiichi drug could tie a second string to its bow, but toxicities might put a dampener on forecasts.